Skip to main content
. 2018 May 22;2018:5389282. doi: 10.1155/2018/5389282

Figure 1.

Figure 1

Aggravation of muscle weakness symptoms in naive and EAMG mice by exposure to NMO-Ig or AQP4 peptide. (a) Injection of AQP4 peptide or NMO-IgG in addition to EAMG induction resulted in aggravation of EAMG weakness symptoms. (b) Mice injected with AQP4 peptide or NMO-IgG had significant muscle weakness as compared to CFA-injected mice. Results are the mean of 3 separated experiments. EAMG control n = 16, EAMG + AQP4 peptide n = 6, EAMG + NMO-Ig n = 7, AQP4 peptide n = 9, NMO-Ig n = 6, and CFA n = 6.